Vertex is ending work on one of its two clinical-stage islet cell treatments after the diabetes therapy looked unlikely to trigger sufficient levels of insulin production in a phase 1/2 trial.

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

See reviews below to learn more or submit your own review. How do I know I can trust these reviews about The Standard Insurance Company? How do I know I can trust these reviews about The Standard ...

The continued progression of the phase 2 trial with our lead asset, personalized cancer vaccine EVX-01, demonstrating convincing one-year interim data and on track for two-year clinical efficacy ...

NEW YORK (AP) — Two books on the history of indigenous people in the U.S. have received $10,000 awards presented by the J. Anthony Lukas Prize Project. Rebecca Nagle's “By the Fire We Carry: The ...

NEW YORK, January 24, 2025--VanEck announces 5-for-1 forward stock split for its EVX ETF.

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

SBI Conservative Hybrid Fund - (IDCW-M) 18.40 2,00,000 0.19 SBI Conservative Hybrid Fund - (IDCW-Q) 18.40 2,00,000 0.19 SBI Conservative Hybrid Fund - (IDCW-A) 18.40 ...

Javascript is required for you to be able to read premium content. Please enable it in your browser settings.